Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
82,244 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 22, 2026 | Independence Blue Cross | Inclisiran (Leqvio)PayerPolicy · IBX-COMMERCIAL-08-01-91 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Imetelstat (Rytelo)PayerPolicy · IBX-COMMERCIAL-08-02-30 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Guselkumab (Tremfya) Injection for Intravenous UsePayerPolicy · IBX-COMMERCIAL-08-02-33 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Golimumab (Simponi Aria) Intravenous (IV) InjectionPayerPolicy · IBX-COMMERCIAL-08-01-15 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Glofitamab-gxbm (Columvi)PayerPolicy · IBX-COMMERCIAL-08-02-07 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Givosiran (Givlaari) and Panhematin (Hemin)PayerPolicy · IBX-COMMERCIAL-08-00-21 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Filgrastim (Neupogen) and Related Biosimilars, and tbo-filgrastim (Granix)PayerPolicy · IBX-COMMERCIAL-08-01-73 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Fam-trastuzumab deruxtecan-nxki (Enhertu)PayerPolicy · IBX-COMMERCIAL-08-00-12 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Evinacumab-dgnb (Evkeeza)PayerPolicy · IBX-COMMERCIAL-08-01-76 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Eptinezumab-jjmr (VYEPTI)PayerPolicy · IBX-COMMERCIAL-08-00-45 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Epcoritamab-bysp (EPKINLY)PayerPolicy · IBX-COMMERCIAL-08-02-12 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme, Elaprase, Vimizim, Naglazyme, Mepsevii, etc.)PayerPolicy · IBX-COMMERCIAL-08-00-70 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Enzyme Replacement Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (e.g., elapegademase-lvlr [Revcovi])PayerPolicy · IBX-COMMERCIAL-08-01-26 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Enfortumab vedotin-ejfv (Padcev)PayerPolicy · IBX-COMMERCIAL-08-00-43 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Emapalumab-lzsg (Gamifant)PayerPolicy · IBX-COMMERCIAL-08-01-54 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Elranatamab-bcmm (Elrexfio)PayerPolicy · IBX-COMMERCIAL-08-02-18 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Efgartigimod alfa - fcab (Vyvgart)PayerPolicy · IBX-COMMERCIAL-08-01-84 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Efbemalenograstim alfa-vuxw (Ryzneuta), Eflapegrastim-xnst (Rolvedon), Pegfilgrastim (Neulasta) and Related BiosimilarsPayerPolicy · IBX-COMMERCIAL-08-01-32 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Eculizumab (Soliris) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris) for intravenous administrationPayerPolicy · IBX-COMMERCIAL-08-00-84 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Durvalumab (Imfinzi) and Tremelimumab-actl (Imjudo)PayerPolicy · IBX-COMMERCIAL-08-01-65 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Dostarlimab-gxly (Jemperli)PayerPolicy · IBX-COMMERCIAL-08-01-79 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Denosumab (Prolia, Xgeva) and related biosimilars, and Romosozumab-aqqg (Evenity)PayerPolicy · IBX-COMMERCIAL-08-00-94 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Datopotamab deruxtecan (Datroway)PayerPolicy · IBX-COMMERCIAL-08-02-41 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Daratumumab (Darzalex), Daratumumab and Hyaluronidase-fihj (Darzalex Faspro)PayerPolicy · IBX-COMMERCIAL-08-01-29 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Crovalimab-akkz (Piasky)PayerPolicy · IBX-COMMERCIAL-08-02-31 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Crizanlizumab-tmca (Adakveo)PayerPolicy · IBX-COMMERCIAL-08-00-04 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Collagenase clostridium histolyticum (Xiaflex ), collagenase clostridium histolyticum-aaes (Qwo)PayerPolicy · IBX-COMMERCIAL-08-01-71 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Cobalamin (Vitamin B12), Folic Acid, and Homocysteine TestingPayerPolicy · IBX-COMMERCIAL-06-02-54 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Chimeric Antigen Receptor Therapy (CART): Carvykti & AbecmaPayerPolicy · IBX-COMMERCIAL-08-02-50 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Chimeric Antigen Receptor (CART) Therapy: Yescarta Tecartus, Breyanzi, Kymriah and AucatzylPayerPolicy · IBX-COMMERCIAL-08-01-43 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Cetuximab (Erbitux)PayerPolicy · IBX-COMMERCIAL-08-00-67 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Cemiplimab-rwlc (Libtayo)PayerPolicy · IBX-COMMERCIAL-08-01-66 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Carfilzomib (Kyprolis)PayerPolicy · IBX-COMMERCIAL-08-01-05 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Canakinumab (Ilaris)PayerPolicy · IBX-COMMERCIAL-08-01-51 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Burosumab-twza (Crysvita)PayerPolicy · IBX-COMMERCIAL-08-01-49 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Brentuximab Vedotin (Adcetris)PayerPolicy · IBX-COMMERCIAL-08-01-13 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Blinatumomab (Blincyto)PayerPolicy · IBX-COMMERCIAL-08-01-21 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Bevacizumab (Avastin) and Related Biosimilars For Oncologic UsePayerPolicy · IBX-COMMERCIAL-08-00-66 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Beremagene Geperpavec (Vyjuvek)PayerPolicy · IBX-COMMERCIAL-08-02-10 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Belimumab (Benlysta) for Intravenous UsePayerPolicy · IBX-COMMERCIAL-08-00-99 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Belantamab mafodotin-blmf (Blenrep)PayerPolicy · IBX-COMMERCIAL-08-02-53 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Axatilimab-csfr (Niktimvo) for Intravenous UsePayerPolicy · IBX-COMMERCIAL-08-02-34 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Avelumab (Bavencio)PayerPolicy · IBX-COMMERCIAL-08-01-64 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Atezolizumab (Tecentriq) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza)PayerPolicy · IBX-COMMERCIAL-08-01-69 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze)PayerPolicy · IBX-COMMERCIAL-08-01-35 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Anifrolumab-fnia (Saphnelo)PayerPolicy · IBX-COMMERCIAL-08-01-82 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro)PayerPolicy · IBX-COMMERCIAL-08-01-90 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Alpha-1 Antitrypsin Therapy (e.g., Prolastin-C, Aralast NP, Glassia, Zemaira)PayerPolicy · IBX-COMMERCIAL-08-00-91 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Alglucosidase alfa (e.g., Lumizyme), Avalglucosidase alfa-ngpt (Nexviazyme ), Cipaglucosidase alfa-atga (Pombiliti )PayerPolicy · IBX-COMMERCIAL-08-00-72 | Codes changed |
|---|
| Aug 22, 2026 | Independence Blue Cross | Alemtuzumab (Lemtrada)PayerPolicy · IBX-COMMERCIAL-08-01-22 | Codes changed |
|---|